Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference
Scios 3 FIB-SEM offers high-powered versatility
The Thermo Scientific™ Scios™ 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with automation to dramatically improve site-specific quality control. The Scios 3 FIB-SEM offers increased productivity for both industry and academia with enhanced lamella preparation, due to advances in FIB column performance. Ease-of-use upgrades will benefit microscopists of all experience levels.
'Researchers across the globe seek new and better materials for various applications – from clean energy and aerospace to productivity of digital devices,' said David Wall, vice president and general manager of materials science for Thermo Fisher. 'The current pace of the development of new materials and their increasing complexity poses significant challenges, and Scios 3 addresses those challenges head-on with world-class advancements designed to serve both academia and industry.'
With advanced automation and high-throughput, Scios 3 improves ease of use, reliability and productivity. To learn more, stop by booth #1734 at M&M for a live demonstration or visit thermofisher.com/scios3.
Talos 12 adapts to researchers across disciplines and experience levels
Thermo Fisher has evolved the popular Talos transmission electron microscope (TEM) design, culminating in the Thermo Scientific Talos™ 12 TEM, making leading-edge sample analysis more accessible than ever for biological research, pathology and drug development.
'We're pleased to introduce Talos 12 at M&M this year to bring transmission electron microscopy to more researchers,' said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. 'A wide array of laboratories can now benefit from this adaptable 120kV instrument. Not only does the reduced footprint and next-generation enclosure fit into more lab spaces, but the streamlined workflows – from routine imaging of cells and tissues to AI-assisted sample characterization to cryo-EM – enable the user-friendly Talos 12 to support remote operation for collaboration regardless of location.'
TEM systems often require highly skilled specialists, but Talos 12 lowers those requirements with new enhancements to improve ease of use while maintaining high quality imaging with high reproducibility. To learn more, stop by booth #1734 at M&M for a live demonstration or visit thermofisher.com/talos12.
Stop by booth #1734 to see Scios, Talos and more
Thermo Fisher will have a significant presence at the Salt Palace Convention Center. In addition to live demonstrations of Scios 3 and Talos 12, several other industry-leading solutions will be on full display.
Stop by booth #1734 to engage with Thermo Fisher subject-matter experts as they discuss the latest advancements in microscopy innovation and analytical research technology.
Additionally, Thermo Fisher has hosted a 'Women in Microscopy' breakfast at M&M for more than two decades and will continue that tradition at the Hyatt Regency on the morning of July 30. Dr. Amelia Dempere, Director of the Nanoscale Research Facility (NRF) at the University of Florida, will talk about her career journey and the ever-increasing importance of women in research.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
Business Wire
9 hours ago
- Business Wire
CORRECTING and REPLACING Zip Marks Fifth Anniversary with New Offices in San Francisco and New York
SAN FRANCISCO--(BUSINESS WIRE)--Please replace the release dated July 24, 2025, with the following corrected version due to multiple revisions. "The fact that Fortune 500 companies across financial services, telecommunications, healthcare, defense, and retail are choosing a five-year-old company over established vendors speaks to how fundamentally we've reimagined procurement." Share The updated release reads: ZIP MARKS FIFTH ANNIVERSARY WITH NEW OFFICES IN SAN FRANCISCO AND NEW YORK Agentic Procurement Orchestration Leader Doubles Office Footprint Amid Explosive Growth, Surpasses Hundreds of Billions in Processed Requests Zip, the world's leading agentic procurement orchestration platform, today celebrated its fifth anniversary by unveiling expanded offices in San Francisco and New York to accommodate rapid workforce growth driven by unprecedented enterprise adoption. The company has grown from 250 to over 500 employees in the past year alone while securing Global 2000 customers across every major industry. Five years ago, Zip's founders chose to tackle procurement – hardly the most glamorous corner of technological innovation. While others chased trendy markets, Zip focused on the overlooked but critical process of how companies buy what they need. Few shared their vision. Then the world changed. Supply chain disruptions, inflation, and tariffs turned procurement from a back-office afterthought into a C-suite priority. What Zip had been quietly building suddenly became every CEO's top concern. That early vision, combined with five years of relentless innovation and AI leadership, explains why global giants from OpenAI to Discover are choosing Zip to transform their operations. 'Over the past five years, we've built something remarkable – a product so sticky that we've maintained 100% retention across our strategic enterprise customers,' said Rujul Zaparde, Co-founder and CEO of Zip. 'The fact that Fortune 500 companies across financial services, telecommunications, healthcare, defense, and retail are choosing a five-year-old company over established vendors speaks to how fundamentally we've reimagined procurement. We've processed over hundreds of billions in total purchasing request volume since our founding five years ago and we've barely scratched the surface of the global opportunity.' From Zero to $2.2 Billion: Five Years of Unprecedented Growth Zip's journey from startup to enterprise standard represents one of the fastest value creation stories in enterprise software history. In October 2024, the company secured $190 million in Series D funding at a $2.2 billion valuation, marking the largest investment in procurement technology in over two decades and validating Zip's position as the category leader. Since its founding in 2020, Zip has achieved milestones that typically take enterprise software companies decades: Customer Momentum: Trusted by hundreds of global enterprises including AMD, Anthropic, Canva, Coinbase, Discover, Lyft, Northwestern Mutual, OpenAI, Pinterest, Reddit, Sephora, and Snowflake Financial Impact: Generated $4.4 billion in customer savings, with companies averaging 3.6% reduction in total spend savings and 25% in productivity gains Product Innovation: Introduced intake to the world, pioneered orchestration, and launched the industry's first agentic AI suite with 50+ procurement agents. Platform has delivered 4.6 million AI insights and achieved unprecedented engagement for an enterprise software platform with 14 million customer comments Doubling Down on Talent and Geographic Expansion To support its trajectory, Zip is hiring aggressively across all markets while significantly expanding its physical footprint: San Francisco: New headquarters doubles office space to 75,000 square feet, housing 200+ employees from top universities like Stanford and MIT, and companies like Meta, Airbnb, and Scale. The expansion reaffirms Zip's commitment to San Francisco as its global headquarters, investing in the city's downtown revitalization New York: Expanding beyond co-working to establish a permanent Manhattan headquarters, positioning Zip closer to financial services and media giants Global Reach: 60+ employees across EMEA, with continued expansion in London The company has grown from approximately 250 employees to over 500 in the past year, hiring 100+ people per quarter, with spending heavily weighted toward R&D. Five Years of Relentless Innovation Zip's trajectory from introducing intake to pioneering agentic procurement orchestration showcases the company's ability to anticipate and shape market needs: 2020: Founded with a vision to fix broken procurement processes; introduced intake and procurement orchestration to the world, transforming how companies start the procurement process 2021: Revolutionized workflows by launching dynamic approvals and integrating with 25+ enterprise systems including ERPs, CLMs, and GRC platforms 2022: Expanded beyond intake to full Procure-to-Pay capabilities, enabling end-to-end procurement orchestration 2023: Became the first procurement platform to embed generative AI, delivering millions of AI-powered insights to customers 2024: Launched the Integration Platform enabling rapid enterprise deployments; established the Zip AI Lab following landmark Series D funding 2025: Introduced Agentic Procurement Orchestration; unveiled suite of 50+ specialized AI agents that autonomously handle complex procurement tasks from tariff analysis to contract reviews 'Five years ago, we introduced intake to the world. We scaled orchestration. Now, we're shaping the agentic future with 50+ AI agents that are redefining what procurement is capable of,' added Lu Cheng, Zip Co-founder and CTO. 'The most exciting part? We're just getting started.' This fall, Zip will host Zip Forward 2025 at San Francisco's Yerba Buena Center for the Arts, where 750+ procurement and finance leaders will gather under the theme 'Agents of Change.' To request an invitation, please visit About Zip Zip is the world's leading agentic procurement orchestration platform, empowering businesses to accelerate the procurement process, mitigate risk, and drive growth by offering a single front door to unify the teams, tasks, and tools involved in working with suppliers. With Zip, businesses can maximize employee adoption of purchasing policies and increase spend visibility and control. As the leading solution for optimizing business spend, Zip's AI-powered platform is trusted by hundreds of leading enterprises worldwide, including AMD, Anthropic, Coinbase, Discover, Dollar Tree, Instacart, Invesco, Lyft, Northwestern Mutual, Prudential, Reddit, Sephora, and Snowflake to maximize the ROI of every dollar. To learn more, visit
Business Wire
12 hours ago
- Business Wire
Sun Nuclear to Highlight New Quality Management Solutions at 2025 AAPM Annual Meeting
MELBOURNE, Fla.--(BUSINESS WIRE)-- Sun Nuclear, a Mirion Medical company, will present significant additions to its comprehensive portfolio of Radiation Therapy Quality Management solutions at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting, taking place July 27-29, in Washington, D.C. Attendees are invited to explore new software and hardware innovations designed to help elevate treatment quality, streamline workflows, and support safer care. Premiering at AAPM 2025 AdaptCHECK™ Software: AdaptCHECK is a groundbreaking quality assurance (QA) solution for adaptive therapy, enabling fast, patient-specific QA for Varian Medical Systems ® Ethos™ Therapy. Built on the SunCHECK ® Patient workflow, AdaptCHECK supports secondary dose calculations for pre-treatment QA, plan-of-the-day calculations for real-time adjustments based on patient anatomy, and quick plan re-calculations to keep treatments on track. Plan AI™ Software: Plan AI* is an AI-powered treatment planning assistant from Oncospace, now part of Sun Nuclear. The application saves time and drives continuous improvement in plan quality by providing predictive, patient-specific insights on achievable goals before planning begins. It further saves time by streamlining communication and accelerating decision-making. SunSILICON™ Detectors: Expanding the Sun Nuclear detector portfolio, SunSILICON detectors mark an intelligent evolution from the widely adopted EDGE Detector™. These precision-engineered silicon diodes are optimized for advanced relative photon and electron dosimetry, designed for SRS and SBRT, and are compatible with the cylindrical SunSCAN™ 3D water phantom. The SunSILICON model is ideal for very small photon fields and electron dosimetry. The shielded SunSILICON P model is optimized for small to large photon fields. evrCAM™ Cameras: A radiation-tolerant pan-tilt-zoom camera, evrCAM offers superior lifetime and low-light visibility, supporting reliable monitoring in radiation environments, efficient clinical workflows and enhanced patient safety. evrCAM is designed for seamless integration into treatment rooms regardless of linac type – providing clinicians with clear video for enhanced patient observation by eliminating pixelated and damaged images. Additional featured solutions include: the latest version of the SunCHECK Platform for centralized, standardized Quality Management; SciMoCa™ for Monte Carlo-based independent verification of online adaptive secondary dose calculations from Elekta ® Unity™ systems; and Gateway™, a patient data conversion solution for Pinnacle™ treatment planning. In-Booth Education and Demonstrations Throughout AAPM 2025, Sun Nuclear will host a series of presentations and hands-on demonstrations in booth 5000. Topics will span AI-powered planning, adaptive QA workflows, detector technology, and clinical use cases—delivered by both internal experts and leading clinical physicists from across the field. 'We are excited to join the medical physics community at AAPM this year, and to present a range of meaningful advancements that reflect our commitment to smarter, safer radiation therapy," said Luis Rivera, President of Sun Nuclear and Executive Vice President of Mirion Medical. "From AI-powered planning tools and adaptive-focused QA to precision detectors and robust monitoring solutions, our expanded portfolio is aimed at helping clinicians drive efficiency, elevate care, and prepare for the future of patient-centric treatment.' To learn more, visit * Plan AI software for prostate and head and neck, thoracic, abdomen, and pelvis radiotherapy is FDA 510(k) cleared, and for sale in the United States only. About Sun Nuclear Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion, providing innovative solutions for Radiation Therapy and Diagnostic Imaging. More than 6,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more: Sun Nuclear, AdaptCHECK, SunCHECK, Plan AI, SunSILICON, SunSCAN 3D and evrCAM are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries. Varian Medical Systems® is a registered trademark, and Ethos™ is a trademark, of Varian Medical Systems, Inc. Sun Nuclear Corporation is not affiliated with or sponsored by Varian Medical Systems, Inc.
